
Opinion|Videos|March 4, 2024
Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From ECOG-ACRIN E1910
Experts present findings on blinatumomab consolidation therapy from the Phase 3 ECOG-ACRIN E1910 trial in adult patients with newly diagnosed B-lineage acute lymphoblastic leukemia who achieved measurable residual disease-negative remission.
Advertisement
Episodes in this series

Advertisement
Related to this article

Amir T. Fathi, MD, explains which assumptions about frontline AML treatment are ready to be challenged in the field.

An external data monitoring committee noted that nemtabrutinib’s benefits in first-line CLL/SLL may not outweigh its risks in the phase 3 BELLWAVE-011 trial.

Amir T. Fathi, MD, outlines what menin inhibitors must show for frontline approval and how to manage differentiation syndrome.

In the phase 1/2 TRANSCEND CLL 004 trial, liso-cel plus ibrutinib produced a 45% CR/CRi rate in a heavily pretreated relapsed/refractory CLL/SLL population.

In the pivotal phase 3 REGAL trial, galinpepimut-S was generally well tolerated among patients with acute myeloid leukemia.
Advertisement
Advertisement
Trending on CancerNetwork
1
Rezatapopt Shows Durable Responses in TP53 Y220C-Mutated PROC
2
Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung Cancer
3
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
4
FDA Grants RMAT Designation to iSCIB1+ in Advanced Melanoma
5


